Evaluating RA in 2020
  • CME

November 5-9, 2020; Virtual Meeting
When is a rheumatoid really a rheumatoid, and what are the implications for telemedicine?
Jonathan Kay, MD
William F. C. Rigby, MD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Released: December 18, 2020 Expiration: December 17, 2021

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Evaluate clinical study results for key studies and consider newly presented data when formulating treatment strategies for patients with RA


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie Inc.
Gilead Sciences, Inc.
Sanofi Genzyme Corporation

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:


William F. C. Rigby, MD

Vice Chair, Department of Medicine
Professor of Medicine, Microbiology and Immunology
Rheumatology Section
The Geisel School of Medicine at Dartmouth
Lebanon, New Hampshire

William F. C. Rigby, MD, has disclosed that he has received funds for contracted research from AbbVie, Bristol-Myers Squibb, Gilead, and Lilly and consulting fees from AbbVie, Bristol-Myers Squibb, and Gilead.
Jonathan Kay, MD

Professor of Medicine and Population and Quantitative Health Sciences
Timothy S. and Elaine L. Peterson Chair in Rheumatology
Division of Rheumatology
Department of Medicine
University of Massachusetts Medical School
Division of Rheumatology
Department of Medicine
UMass Memorial Medical Center
Worcester, Massachusetts

Jonathan Kay, MD, has disclosed that he has received consulting fees from AbbVie, Boehringer Ingelheim, Celltrion, Jubilant Radiopharm, Pfizer, Samsung Bioepis, Sandoz, Scipher Medicine, and Union Chimique Belge and funds for research support from Gilead Sciences, Novartis, and Pfizer.


Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Anne Roc, PhD
Director, Scientific Services
Anne Roc, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for rheumatologists, primary care clinicians, and other healthcare providers who care for patients with RA.


The goal of this activity is to arm clinicians with the most current clinical and scientific advances in RA so that they can apply the latest evidence to optimally manage patients and achieve long-term remission.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately !!AvailableCredits!! hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 18, 2020, through December 17, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least !!PassingPercentage!!% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Stanley B. Cohen, MD, answers questions about the ACR 2020 Pharmacologic Recommendations for the management of RA.

Stanley B. Cohen, MD Released: December 23, 2020

Maria Danila, MD, MSc, MSPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 18, 2020 Expired: December 17, 2021

From ACR/ARP 2020: expert-authored commentary on tapering RA therapy, as reported by Clinical Care Options (CCO)

Jonathan Kay, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 18, 2020 Expired: December 17, 2021

Safety: Frequently asked questions from the CCO Webinar series, “ A Closer Look at Evolving Treatment Strategies for Rheumatoid Arthritis”

Stanley B. Cohen, MD Sheetal Desai, MD, MSEd Eric M. Ruderman, MD Released: December 18, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.